The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus
Abstract
To evaluate the predictive power of changes in levels of antibodies to double‐stranded DNA (anti‐dsDNA) as a predictor of disease exacerbations in systemic lupus erythematosus (SLE), we performed a prospective study on 72 unselected patients with SLE (mean duration of study 18.5 months, range 6–35 months). Patients were seen at least once every 3 months, and disease activity was scored according to a specific protocol. Plasma samples were obtained at least once every month and were assessed for anti‐dsDNA antibody (by the Crithidia luciliae assay, an enzymelinked immunosorbent assay [ELISA], and the Farr assay) and for complement components C3 and C4. Twenty‐seven of 33 disease exacerbations observed during the study period were accompanied by a positive test result for anti‐dsDNA antibody (27 by the Farr assay, 19 by the C luciliae assay, and 23 by the ELISA). Twenty‐four of these exacerbations were preceded by a significant increase in anti‐dsDNA antibody levels (23 by the Farr assay, 12 by the C luciliae assay, and 17 by the ELISA). The first observance of a significant increase in anti‐dsDNA antibody levels preceded the exacerbation by 8–10 weeks. Significant increases in anti‐dsDNA antibody levels not followed by an exacerbation were observed in 5 cases by the Farr assay, in 7 cases by the C luciliae assay, and in 3 cases by the ELISA; however, in 3 cases, 2 cases, and 1 case, respectively, these increases were followed by an increase in disease activity that did not fulfill the criteria for an exacerbation. Serial measurement of anti‐dsDNA antibody levels was more sensitive for predicting exacerbations than was measurement of C3 and/or C4 levels ( P < 0.03). Serial assessment of anti‐dsDNA antibody levels, especially by the Farr assay, is a sensitive and reasonably specific method for predicting disease exacerbations in SLE.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antibodies to dsDNA are an important laboratory parameter for diagnosis, monitoring and classification of systemic lupus erythematosus (SLE).”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [12]
In the citing paper
“positive anti-dsDNA is an important component of the classification criteria for diagnosing SLE”
In the citing paper
“serial measurement of anti-dsDNA is often used to monitor lupus disease activity, especially lupus nephritis (LN).”
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Autoantibodies to Nuclear Antigens (ANA): Their Immunobiology and Medicine
Tan, E. M. (1982) · Advances in Immunology · doi:10.1016/s0065-2776(08)60836-6 · Cited by 965
Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus
Schur, P. H., & Sandson, J. (1968) · New England Journal of Medicine · doi:10.1056/nejm196803072781004 · Cited by 587
Aarden, L. A., Groot, E. R. D., & Feltkamp, T. E. W. (1975) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1975.tb29197.x · Cited by 563
ANTIBODIES TO POLYNUCLEOTIDES IN HUMAN SERA: ANTIGENIC SPECIFICITY AND RELATION TO DISEASE
Koffler, D., Carr, R., Agnello, V., Thoburn, R., & Kunkel, H. G. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.134.1.294 · Cited by 510
Measurement of Serum DNA-Binding Activity in Systemic Lupus Erythematosus
Pincus, T., Schur, P. H., Rose, J. A., Decker, J. L., & Talal, N. (1969) · New England Journal of Medicine · doi:10.1056/nejm196909252811304 · Cited by 441
Anti‐dsdna and complement profiles as prognostic guides in systemic lupus erythematosus
Swaak, A. J. G., Aarden, L. A., Statius Eps, L. W. V., & Feltkamp, T. E. W. (1979) · Arthritis & Rheumatism · doi:10.1002/art.1780220304 · Cited by 284
Immune Complexes, Complement, and Anti-DNA in Exacerbations of Systemic Lupus Erythematosus (SLE)
LLOYD, W., & SCHUR, P. H. (1981) · Medicine · doi:10.1097/00005792-198105000-00004 · Cited by 242
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
Swaak, A. J., Groenwold, J., & Bronsveld, W. (1986) · Annals of the Rheumatic Diseases · doi:10.1136/ard.45.5.359 · Cited by 224
Faaber, P., Rijke, T. P., van de Putte, L. B., Capel, P. J., & Berden, J. H. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112508 · Cited by 224
Research works printed but not linked: 2
- Wallace DJ, 1987, Lupus Erythematosus
- Cameron JS, 1976, Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations., Clin Exp Immunol, 25, 418
Cited by
Rahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372
“The blue line is “Ins(1,3,4,5)P4 (300 μM)” and the green line is “Ins(1,4,5,6)P4 (300 μM).”
BackgroundInfluentialHuman lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9
Means, T. K., Latz, E., Hayashi, F., Murali, M. R., Golenbock, D. T., & Luster, A. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523025 · Cited by 849
“These autoantibodies are thought to contribute directly to the pathogenesis of SLE, as they precede the development of clinical disease in most patients, and levels of anti-DNA antibodies correlate with disease activity (4, 5).”
BackgroundTreat-to-target in systemic lupus erythematosus: recommendations from an international task force
van Vollenhoven, R. F., Mosca, M., Bertsias, G., Isenberg, D., Kuhn, A., Lerstrøm, K., Aringer, M., Bootsma, H., Boumpas, D., Bruce, I. N., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205139 · Cited by 740
Hahn, B. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805073381906 · Cited by 682
Metadata
- Authors
- Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M.
- Affiliations
- University Medical Center Groningen (NL)
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1990-05
- Volume
- 33
- Issue
- 5
- Pages
- 634-643
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2113059823
- Cited by
- 572
- References
- 34
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 18 · 2019: 14 · 2018: 16 · 2017: 14 · 2016: 15 · 2015: 24 · 2014: 27 · 2013: 24 · 2012: 22
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arthritis & Rheumatism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- systemic lupus erythematosus, anti-dsDNA antibodies, disease exacerbation, disease activity prediction, complement C3, complement C4, Farr assay, ELISA
- MeSH terms
- Adolescent, Adult, Aged, Antibodies, Antinuclear, Complement C3, Complement C4, DNA, Enzyme-Linked Immunosorbent Assay, Female, Forecasting, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. https://app.cochat.ai/papers/10.1002/art.1780330505
- The paper
- Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990). Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis & Rheumatism. https://doi.org/10.1002/art.1780330505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.